Association of Four Genetic Polymorphisms of AGER and Its Circulating Forms with Coronary Artery Disease: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Peng, Feng ^a   Hu, Dan ^b   Jia, Nan ^c,d   Li, Xiaobo ^c,d   Li, Yuqiong ^c,d   Chu, Shaoli ^c,d   Zhu, Dingliang ^c,d   Shen, Weifeng ^c   Lin, Jinxiu ^a   Niu, Wenquan ^c,d  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Shanghai Institute of Hypertension   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR;

ADULT; AGED; AGER GENE; ALLELE; ARTICLE; BODY MASS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; RISK ASSESSMENT; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE;

EID: 84880851277     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070834     Document Type: Article

References (46)

1. Niu W, Liu Y, Qi Y, Wu Z, Zhu D, et al. (2012) Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol 157: 243-252.
2. Hegab Z, Gibbons S, Neyses L, Mamas MA, (2012) Role of advanced glycation end products in cardiovascular disease. World J Cardiol 4: 90-102.
3. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, et al. (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25: 1032-1037.
4. Koyama H, Yamamoto H, Nishizawa Y, (2007) RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 13: 625-635.
5. Park HJ, Baek JY, Shin WS, Kim DB, Jang SW, et al. (2011) Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J 75: 1685-1690.
6. Wang J, Zou L, Song Z, Lang X, Huang S, et al. (2012) Meta-analysis of RAGE gene polymorphism and coronary heart disease risk. PLoS One 7: e50790.
7. Hudson BI, Stickland MH, Futers TS, Grant PJ, (2001) Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50: 1505-1511.
8. Peng WH, Lu L, Wang LJ, Yan XX, Chen QJ, et al. (2009) RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. Arch Med Res 40: 393-398.
9. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, W264.
10. Bowden J, Tierney JF, Copas AJ, Burdett S, (2011) Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol 11: 41.
11. Falcone C, Campo I, Emanuele E, Buzzi MP, Zorzetto M, et al. (2004) Relationship between the-374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med 14: 1061-1064.
12. Kirbis J, Milutinovic A, Steblovnik K, Teran N, Terzic R, et al. (2004) The-429 T/C and-374 T/A gene polymorphisms of the receptor of advanced glycation end products gene (RAGE) are not risk factors for coronary artery disease in Slovene population with type 2 diabetes. Coll Antropol 28: 611-616.
13. dos Santos KG, Canani LH, Gross JL, Tschiedel B, Pires Souto KE, et al. (2005) The-374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Mol Genet Metab 85: 149-156.
14. Hofmann MA, Yang Q, Harja E, Kedia P, Gregersen PK, et al. (2005) The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. Atherosclerosis 182: 301-305.
15. Zee RY, Romero JR, Gould JL, Ricupero DA, Ridker PM, (2006) Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke. Stroke 37: 1686-1690.
16. Yoon SJ, Park S, Shim CY, Park CM, Ko YG, et al. (2007) Association of RAGE gene polymorphisms with coronary artery disease in the Korean population. Coron Artery Dis 18: 1-8.
17. Lu L, Jin Pu L, Chen QJ, Wang L, Peng W, et al. (2008) Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients. Clin Chim Acta 396: 33-37.
18. Mulder DJ, van Haelst PL, Gross S, de Leeuw K, Bijzet J, et al. (2008) Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 197: 217-223.
19. Kucukhuseyin O, Aydogan HY, Isbir CS, Isbir T, (2009) Associations of-374T/A polymorphism of receptor for advanced glycation end products (RAGE) gene in Turkish diabetic and non-diabetic patients with coronary artery disease. In Vivo 23: 949-954.
20. Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, et al. (2009) Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 206: 540-545.
21. Mahajan N, Malik N, Bahl A, Dhawan V, (2009) Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 207: 597-602.
22. Pu L, Lu L, Shen W, Zhang Q, Fang D, et al. (2009) Relation of serum levels of endogeneous secretory receptor for advanced glycation end products and glycation albumin to coronary artery disease in type 2 diabetes mellitus. Chinese Journal of Microcriculation 19(4): 24-26.
23. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, et al. (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205: 544-548.
24. Gao J, Shao Y, Lai W, Ren H, Xu D, (2010) Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population. J Hum Genet 55: 668-675.
25. McNair ED, Wells CR, Mabood Qureshi A, Basran R, Pearce C, et al. (2010) Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 33: 678-685.
26. McNair ED, Wells CR, Mabood Qureshi A, Basran R, Pearce C, et al. (2010) Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 341: 135-138.
27. Xie G, Chen Y, Xiao H, Han C, Chen J, (2010) Association of-374T/A polymorphism of RAGE gene with coronary heart disease in Chinese Han population. South China Journal of Cardiovascular Diseases 16: 468-470.
28. Boiocchi C, Bozzini S, Buzzi MP, Schirinzi S, Zorzetto M, et al. (2011) Age of onset of myocardial infarction: is promoter polymorphism of the RAGE gene implicated? Rejuvenation Res 14: 67-73.
29. Cai XY, Lu L, Wang YN, Jin C, Zhang RY, et al. (2011) Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury. Atherosclerosis 217: 536-542.
30. Hou X, Jin J, Han S, Song Y, He X, (2011) The study of the relationship between single-nucleotide polymorphism of receptor for advanced glycation end products and coronary angiography in a Positive. Prevention and Treatment of Cardio-Carebral-Vascular Disease 11: 272-274.
31. Lu W, Xie G, Feng B, Liu F, (2011) Association of RAGE gene polymorphisms with the presence and the severity of coronary artery disease in non-diabetic Han populations. Journal of Soochow University Medical Science Edition 31: 454-458.
32. Peng WH, Jian WX, Li HL, Hou L, Wei YD, et al. (2011) Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol 10: 41.
33. Aydogan HY, Kucukhuseyin O, Tekeli A, Isbir T, (2012) Associations of receptor for advanced glycation end products-374 T/A and Gly82 Ser and peroxisome proliferator-activated receptor gamma Pro12Ala polymorphisms in Turkish coronary artery disease patients. Genet Test Mol Biomarkers 16: 134-137.
34. Selejan SR, Poss J, Hewera L, Kazakov A, Bohm M, et al. (2012) Role of receptor for advanced glycation end products in cardiogenic shock. Crit Care Med 40: 1513-1522.
35. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, et al. (2008) Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 17: 983-996.
36. Hou FF, Ren H, Owen WF Jr, Guo ZJ, Chen PY, et al. (2004) Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15: 1889-1896.
37. Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, et al. (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47: 406-411.
38. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, et al. (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76: 52-56.
39. Chen G, Wu Y, Wang T, Liang J, Lin W, et al. (2012) Association between serum endogenous secretory receptor for advanced glycation end products and risk of type 2 diabetes mellitus with combined depression in the Chinese population. Diabetes Technol Ther 14: 936-942.
40. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, et al. (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204: 288-292.
41. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, et al. (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835.
42. Yan SF, D'Agati V, Schmidt AM, Ramasamy R, (2007) Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 7: 699-710.
43. Niu W, Qi Y, Wu Z, Liu Y, Zhu D, et al. (2012) A meta-analysis of receptor for advanced glycation end products gene: four well-evaluated polymorphisms with diabetes mellitus. Mol Cell Endocrinol 358: 9-17.
44. Li Y, Li X, Jia N, Guo S, Chu S, et al. (2013) Meta-analysis of the association between angiotensin II receptor, type 1 gene A1166C polymorphism and coronary artery disease in Chinese populations. J Renin Angiotensin Aldosterone Syst 14: 82-90.
45. Zintzaras E, Raman G, Kitsios G, Lau J, (2008) Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis. Arch Intern Med 168: 1077-1089.
46. Niu W, Qi Y, (2012) Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: systematic review and meta-analysis. Heart 98: 1483-1491.